French Competition Body Fines Janssen €25m For Delaying Generic Durogesic
Executive Summary
Janssen-Cilag has been fined €25m by the French competition authority for running a concerted campaign to prevent generic competition to its fentanyl-containing analgesic drug Durogesic. The French medicines regulator does not come out of the affair well either.
You may also be interested in...
Generic smear campaign earns Merck French fine
The French competition authority has fined Merck & Co's Schering-Plough business €15.3m for attempting to block from the market a generic version of its opioid addiction drug Subutex (buprenorphine).
Sanofi fined for smear campaign against generic Plavix
Sanofi has been fined €40.6 million by the French competition authority for abusing a dominant market position to run a smear campaign against generic versions of its blockbuster antithrombotic Plavix (clopidogrel).
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.